Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer

Affordable Access

Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer

Authors
Publisher
American Association for Cancer Research
Keywords
  • 111200 Oncology And Carcinogenesis

Abstract

CIBCB_2005-39.pdf 0-7803-9387-2/05/$20.00 ©2005 IEEE Artificial Neural Network Analysis of DNA Microarray-based Prostate Cancer Recurrence Leif E. Peterson, Mustafa Ozen, Halime Erdem, Andrew Amini, Lori Gomez, Colleen C. Nelson, and Michael Ittmann Abstract—DNA microarray-based gene expression profiles have been established for a variety of adult cancers. This paper addresses application of an artificial neural network (ANN) with leave-one- out testsing and 8-fold cross-validation for analyz- ing DNA microarray data to identify genes predic- tive of recurrence after prostatectomy. Among 725 genes screened for ANN input, a 16-gene model re- sulted in 99-100% diagnostic sensitivity and speci- ficity: DGCR5, FLJ10618, RIS1, PRO1855, ABCB9, AK057203, GOLGA5, HARS, AK024152, HEP27, PPIA, SNRPF, SULT1A3, SECTM1, EIF4EBP1, and S71435. Genes identified with ANN that are prognostic of prostate cancer recurrence may be either causal for prostate cancer or secondary to the disease. Neverthe- less, the genes identified may be confirmed in the future to be markers of early detection and/or therapy. I. Introduction Prostate cancer is the 2nd leading cause of cancer mor- tality among US males[1]. For locally confined cancer, cu- rative treatment includes radical prostatectomy [2,3] and radiotherapy[4-7]. Following prostatectomy, it is expected that serum levels of prostate specific antigen (PSA) remain fixed below a level of 0.2 ng/ml. However, approximately 15-35% of patients experience PSA (biochemical) recur- rence defined as two or more successive follow-up values of PSA>0.2 ng/ml more than 30 days post-surgery [8-11]. Early biochemical recurrence occurring before 1 year post- surgery is strongly associated with metastatic disease in approximately 75% of male patients[12]. However, clin- ical and pathological factors are imperfect predictors of biochemical recurrence. Thus, it is of interest to augment clinical information with prognostic information derived from molecular markers of

There are no comments yet on this publication. Be the first to share your thoughts.